- cafead   Nov 30, 2020 at 11:22: PM
via Revance will have to wait for an FDA decision on its frown-line injection daxibotulinumtoxinA after the FDA admitted it couldn't inspect the company's Newark, California manufacturing facility on time because of COVID-19 restrictions.
article source
article source